Study Objectives: To develop and validate a practical model for obstructive sleep apnea (OSA) screening in adults based on objectively assessed criteria, and then compare it with two widely used tools, namely STOP-BANG and NoSAS. Methods: This is a retrospective study of an existing database of consecutive outpatients who were referred for polysomnography for suspected sleepdisordered breathing by their primary care physicians. Area under the curve (AUC) and 2 × 2 contingency tables were employed to obtain the performance of the new instrument. Results: A total of 4,072 subjects were randomly allocated into two independent cohorts: one for derivation (n = 2,037) and one for validation (n = 2,035). A mnemonic model, named No-Apnea, with two variables (neck circumference and age) was developed (total score: 0-9 points). We used the cutoff ≥ 3 to classify patients at high risk of having OSA. OSA severity was categorized by apnea-hypopnea index (AHI): any OSA (AHI 5 ≥ events/h; OSA-5), moderate/ severe OSA (AHI 15 ≥ events/h; OSA-15); and severe OSA (AHI 30 ≥ events/h; OSA-30). In the derivation cohort, the AUCs for screening of OSA-5, OSA-15, and OSA-30 were: 0.784, 0.758, and 0.754; respectively. The rate of subjects correctly screened was 78.1%, 68.8%, and 54.4%, respectively for OSA-5, OSA-15, and OSA-30. Subsequently, the model was validated confirming its reproducibility. In both cohorts, No-Apnea discrimination was similar to STOP-BANG or NoSAS.
I NTRO DUCTI O N
Obstructive sleep apnea (OSA) is characterized by frequent partial or complete collapse of the upper airway during sleep, resulting in periodic hypoxemia, increased respiratory effort, and arousals. 1 There is growing evidence of OSA playing a role in the pathogenesis of cardiovascular and metabolic diseases 1 and also a strong association with increased mortality rates. 2 Recent studies [3] [4] [5] indicate a clear increase in the prevalence of OSA: a Brazilian study showed that OSA was diagnosed in 32.8% of the participants 3 ; two other studies have also shown
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Simplifying the Screening of Obstructive Sleep Apnea With a 2-Item Model, No-Apnea: A Cross-Sectional Study similar findings, with a prevalence of moderate to severe OSA of 13% being recorded among men and of 6% among women 4 and of 49.7% in men and 23.4% in women. 5 Aging populations 6 and the strong association between body mass index (BMI) and OSA 7 may account for such increases in OSA prevalence. Indeed, obesity has been linked with increases in neck circumference (NC), which can reduce the upper airway diameter and alter the mechanical properties of the upper airway altogether. 8, 9 The gold standard for OSA diagnosis consists of full polysomnography (PSG); however, it is not readily available for the large number of patients with suspected OSA, such that a screening tool could be useful to stratify patients at risk for OSA, and enable improved access to PSG testing and diagnosis. 10 Several OSA screening questionnaires have been described, [11] [12] [13] [14] [15] [16] among which the Berlin and STOP-BANG instruments are most frequently cited. The Berlin questionnaire 12 includes items that access the presence and frequency of snoring, sleepiness or fatigue, and history of obesity or hypertension. The STOP questionnaire (snoring, tiredness, observed apnea, and hypertension), and the STOP-BANG questionnaire (STOP plus BMI, age, NC, and gender) were first developed and validated in surgical patients. 13 Both questionnaires are self-administered consisting of 4 or 8 yes-orno questions, respectively. For OSA diagnosis in a sample of surgical patients, the STOP-BANG questionnaire showed the following parameters: sensitivity 83.6%, specificity 56.4%, positive predictive value (PPV) 81.0%, and negative predictive value (NPV) 60.8%. 13 Despite the extensive efforts to develop highly performing questionnaires, objectively based scoring tools for screening of OSA have rarely been evaluated. Indeed, the existing OSA screening models rely on subjective information, such as snoring, observed apnea, and choking/gasping, usually provided by the bed partner, and therefore not always available. To overcome such constraints in the screening of OSA, our study comprised two parts: (1) development and validation of a very practical screening model and (2) comparison with STOP-BANG questionnaire 13 and the recently reported NoSAS score.
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Study Design and Patient Selection
This is a cross-sectional retrospective study of an existing database from January 2015 to December 2016 of consecutive outpatients who were referred for PSG evaluation for suspected sleep-disordered breathing (SDB) by their primary care physicians. If the same patient underwent more than one test, only the test that had the highest total sleep time was retained. All subjects were grouped into two different and independent samples, using a randomization process as prescribed by the SPSS statistical package (version 17.0; SPSS; Chicago, Illinois, United States), in which all patients enrolled in the study were divided equally into two cohorts (50% of the patients were allocated to the derivation cohort and the remaining 50% were allocated to the validation cohort). Our study protocol (#666.608) was approved by the Institutional Review Board of Federal University of Rio de Janeiro and waived the patient consent requirement. For both groups, inclusion criteria consisted of age 18 years or older and suspected OSA, whereas they were excluded for any of the following reasons: previously diagnosed OSA, use of portable or split-night studies, incomplete clinical data, and technically inadequate PSG. On the evening of the PSG, clinical data were collected in all patients: sex, age, BMI, NC, self-reported comorbidities (hypertension, diabetes mellitus, and smoking), and Epworth Sleepiness Scale (ESS), 17 which is a well-validated 8-item questionnaire that measures subjective sleepiness, with a score of 10 points or higher considered indicative of excessive daytime sleepiness. Patients were measured for weight and height, and the BMI was calculated by dividing the weight in kilograms by the square of the height in meters (kg/m 2 ). The NC was systematically measured, using a tape measure, in centimeters, as follows: all subjects were asked to stand erect with their head positioned in the Frankfort horizontal plane. The superior border of a tape measure was placed just below the laryngeal prominence and applied perpendicular to the long axis of the neck. 18 Aiming to compare with other validated models, data from the STOP-BANG questionnaire 13 and NoSAS score 16 were also collected by trained sleep technicians. The STOP-BANG 13 consists of 8 yes-or-no questions: loud snoring, tiredness, observed apnea, hypertension, BMI > 35 kg/m 2 , age older than 50 years, NC > 40 cm, and male sex. A score of 3 or higher is considered as high risk for presence of OSA. The NoSAS score 16 allocates 4 points for having a NC > 40 cm, 3 points for having a BMI of 25 kg/m 2 to less than 30 kg/m 2 or 5 points for having a BMI ≥ 30 kg/m 2 , 2 points for snoring, 4 points for age older than 55 years, and 2 points for being male. Using NoSAS, a cutoff of ≥ 8 points identifies subjects at risk of clinically significant SDB.
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Sleep Studies
All Brazilian studies were conducted in a single sleep center with two different units: one in Niteroi City and one in Rio de Janeiro City. All patients underwent an attended, in-laboratory PSG (EMBLA S7000, Embla Systems, Inc., Broomfield, Colorado, United States), consisting of continuous monitoring of electroencephalography, electrooculography, electromyography (chin and legs), electrocardiography, airflow (nasal pressure), thoracic and abdominal impedance belts, oxygen saturation (SpO 2 ), microphone for snoring, and sensors for body position. PSG records were scored manually and were interpreted in a blinded way by two board-certified sleep physicians in accordance with existing guidelines. 19 Apneas were classified with a drop ≥ 90% of baseline in airflow lasting at least 10 seconds, whereas hypopneas were classified as follows: a drop ≥ 30% of preevent during ≥ 10 seconds associated with ≥ 3% oxygen desaturation or an arousal.
19 Diagnosis of OSA was based on an apnea-hypopnea index (AHI) ≥ 5 events/h and its severity was classified as follows: ≥ 5 events/h as any OSA (OSA-5), ≥ 15 events/h as moderate/severe OSA (OSA-15), and ≥ 30 events/h as severe OSA (OSA-30).
Modeling
We aimed to elaborate a very practical model that contains only continuous and numerical variables, and as such three parameters, previously recognized as predictors of OSA, were chosen for analysis: NC, age, and BMI. First, these variables were evaluated through linear regression in order to verify the occurrence or not of multicollinearity. Multicollinearity is a linear association between two or more explanatory variables being detected by tolerance and variance inflation factor (VIF). 20 The VIF is simply the reciprocal of the tolerance level (1/tolerance), being that the VIFs measure the inflation in the variances of the parameter estimates due to collinearities that exist among the predictors. 20 After excluding multicollinearity, these three parameters were evaluated in their continuous form, through binary logistic regression at three different AHI thresholds (5, 15 , and 30 events/h), with comparisons being conducted through the regression coefficient (β). To further simplify the model, the two main parameters were retained. For the elaboration of the scoring system, these two parameters were grouped based on three cutoff points obtained by median (50% percentile) and interquartile range (IQR: 25% and 75% percentiles) and then evaluated with binary logistic regression. Assignment of points to parameters was calculated as follows: the β coefficient of each variable was divided by the lowest β-coefficient value and rounded to the nearest whole integer. Subsequently, all points accrued were summed to create the scoring index.
Statistical Analysis
Data analysis was conducted using SPSS for Windows (version 17.0; SPSS; Chicago, Illinois, United States). Results are shown as median and IQR for continuous variables and as frequency with percentage for categorical variables. Groups were compared using the chi-square test for categorical variables, whereas all numeric variables were evaluated with the nonparametric Mann-Whitney U test. Correlation was evaluated by Spearman correlation coefficient (r s ). Through linear regression, absence of multicollinearity was assumed if VIF < 5.0. Parameters predictive of OSA (age, NC, and BMI) were entered into a logistic regression analysis in parallel, with the Wald test being used to explore if explanatory variables in a model were significant. A scoring system was derived using weightings from β-regression coefficients.
To examine the apparent performance (internal validity) of our developed model, discrimination, calibration, and overall performance were calculated in both cohorts evaluated. Discrimination, the ability of a scoring system to distinguish between patients with and without different outcomes, was estimated from the area under the curve (AUC). 21 The AUC may theoretically range from 0.5 (discrimination equivalent to that of chance) to 1.0 (perfect discrimination). 21 Calibration refers to the agreement between observed outcomes and predictions; being that it was assessed by Hosmer-Lemeshow chi-square test (P < .05 indicates poor calibration). 21 Overall performance (how well the model predicts the likelihood of an outcome in an individual patient) was assessed using the Nagelkerke R 2 , which ranges from 0 to 1. 21 As the Hosmer-Lemeshow chi-square test is sensitive to sample size, we chose smaller subsets of randomly selected patients (n = 1,000) to evaluate the model calibration in both cohorts evaluated. After completion of the model development, the cutoff point determined to identify patients at risk for SDB was chosen to achieve a high sensitivity, while preserving a moderate specificity. Using the 2 × 2 contingency tables, the following parameters were calculated: sensitivity, specificity, PPV, NPV, accuracy, likelihood ratios, and odds ratio (OR) with their respective 95% confidence interval (CI). The receiver operating characteristic (ROC) curves and AUC were assessed at three AHI thresholds (5, 15 , and 30 events/h). The AUCs obtained by all screening models were compared using prior algorithm. 22 Posttest probability of each score was calculated by logistic regression. A two-tailed value of P < .05 was considered statistically significant.
R ESU LT S
Of a total of 4,476 subjects referred for diagnostic PSG, 404 patients (9.0%) were subsequently excluded based on exclusion criteria. The exclusions consisted of 260 with incomplete clinical data, 76 tested with portable or split-night studies, 54 with technically inadequate PSG, and 14 with a previous diagnosis of OSA. Thus, 4,072 subjects were randomly allocated into two independent cohorts: one for derivation (n = 2,037) and one for validation (n = 2,035). Based on 
The No-Apnea Development
After excluding multicollinearity among the three parameters of interest (NC with VIF = 1.484, age with VIF = 1.016, and BMI with VIF = 1.503), these variables were evaluated through binary logistic regression ( Table 2) . As can be seen in Table 2 , for all AHI thresholds (5, 15 or 30 events/h), when comparing the three clinical parameters in their continuous form, we found that the magnitude of the regression coefficient was always higher for NC, followed by age and BMI. Moreover, BMI did not emerge as an independent variable for screening of OSA-5 with OR: 1.014 (95% CI: 0.996-1.033; P = .119). Therefore, BMI was then excluded from the model for three reasons: (1) in the binary logistic regression, it was the third-ranked parameter for all AHI thresholds; (2) it did not emerge as an independent parameter for screening of OSA-5; and (3) reducing the model to two variables obviously further simplified the tool. Table 3 shows the binary logistic regression with the two parameters chosen (NC and age) categorized from the 25%, 50% and 75% percentiles: (1) for NC: 37 cm, 40 cm, and 43 cm; and (2) for age: 35 years, 45 years, and 55 years; respectively. Data are presented as median (interquartile range) or n (%). AHI = apnea-hypopnea index, BMI = body-mass index, ESS = Epworth sleepiness scale, NC = neck circumference, PSG = polysomnography, REM = rapid eye movement, SpO2 = oxygen saturation. The P value was obtained from the Wald test. All parameters were entered into logistic regression in parallel. AHI = apnea-hypopnea index, β = regression coefficient, BMI = body mass index, CI = confidence interval, df = degrees of freedom for the Wald test, NC = neck circumference, OR = odds ratio, SE = standard error.
Then, each variable was grouped and scored, according to β-coefficient, as follows: the NC (in cm) was scored in three different values: 1 (37.0-39.9), 3 (40.0-42.9), and 6 (≥ 43.0), whereas the age (in years) was scored in three different values: 1 (35-44), 2 (45-54), and 3 (≥ 55). The points for each variable were added, totaling a final score of 0-9 points and this mnemonic tool was termed "No-Apnea" ( Table 4) . The most frequent No-Apnea score was 3 points (n = 352), followed by 6 points (n = 314) and 4 points (n = 263). Corresponding to the increase in No-Apnea scores (from 0 to 9 points), there was a linear increase in the prevalence of OSA-5 (from 33.0% to 95.6%), OSA-15 (from 13.6% to 85.3%), and OSA-30 (from 3.9% to 68.4%); all with P < .001.
The No-Apnea Performance
In the derivation cohort, for screening of OSA-5 (the AHI threshold chosen to score the No-Apnea parameters) , the developed model showed the following characteristics: (1) 
The No-Apnea Predictive Parameters (Derivation Cohort)
Predictive performance of the No-Apnea is shown in Table 5 (derivation cohort; n = 2,037). We used a cutoff of ≥ 3 to classify patients at high risk (75.9%) versus at low risk (24.1%) of having OSA-5, OSA-15, and OSA-30. The accuracies obtained were of 78.1%, 68.8%, and 54.4%, respectively for OSA-5, OSA-15, and OSA-30. Using a cutoff of ≥ 3, the posttest probabilities for OSA-5, OSA-15, and OSA-30 were 86.8%, 65.8%, and 42.6%, respectively. In addition, the posttest probabilities for OSA-5, OSA-15, and OSA-30 increased proportionally with the increase in the No-Apnea scores (from 0 to 9 points; data not shown). Table 6 was created aiming to compare our model with two previously reported screening tools: STOP-BANG and NoSAS. For screening of OSA-5, OSA-15, and OSA-30, No-Apnea model showed the following parameters: sensitivity ranged from 84.7% to 94.0%, specificity ranged from 54.9% to 33.6%, whereas the accuracy ranged from 78.1% to 54.4%, respectively. For OSA-5 diagnosis, STOP-BANG showed the higher sensitivity (88.8%), whereas the higher specificity was obtained with NoSAS (68.7%). For OSA-15 diagnosis, NoSAS showed the higher specificity (57.6%), whereas the higher sensitivity was obtained with STOP-BANG (92.5%). For OSA-30 diagnosis, NoSAS showed the higher specificity (49.2%), whereas the higher sensitivity was obtained with STOP-BANG (95.7%). Based on AUCs, NoApnea discrimination did not show statistically significant differences compared to the STOP-BANG for screening of OSA-5 The P value was obtained from the Wald test. * = points assigned to No-Apnea from the regression coefficient. AHI = apnea-hypopnea index, β = regression coefficient, CI = confidence interval, df = degrees of freedom for the Wald test, OR = odds ratio, SE = standard error. The points for each variable are added, totaling a final score of 0-9 points.
(P = .645), OSA-15 (P = .946), and OSA-30 (P = .589). Similarly, No-Apnea discrimination did not significantly differ from that of NoSAS for screening of OSA-5 (P = .555), OSA-15 (P = .946), and OSA-30 (P = .858). Furthermore, STOP-BANG discrimination was similar to NoSAS for diagnosis of OSA-5, OSA-15, and OSA-30: P = .896, P = .892, and P = .473; respectively. All models tested (No-Apnea, STOP-BANG, and NoSAS) were correlated with AHI (r s = 0.530, r s = 0.545, and r s = 0.529; respectively; all with P < .001). In addition, ESS has not proved useful as a screening tool for OSA-5, OSA-15, and OSA-30: AUC: 0.573 (95% CI: 0.543-0.603), AUC: 0.559 (95% CI: 0.534-0.584), and AUC: 0.591 (95% CI: 0.565-0.617); respectively.
The No-Apnea Predictive Parameters (Validation Cohort)
Based on AUCs summarized in the Table 7 (validation cohort; n = 2,035), No-Apnea discrimination did not show statistically significant differences compared to the STOP-BANG for screening of OSA-5 (P = .232), OSA-15 (P = .087), and OSA-30 (P = .074). Similarly, No-Apnea discrimination did not significantly differ from that of NoSAS for screening of OSA-5 (P = .957), OSA-15 (P = .788), and OSA-30 (P > .999). In addition, STOP-BANG discrimination was similar to NoSAS for diagnosis of OSA-5, OSA-15, and OSA-30: P = .212, P = .085, and P = .074; respectively. For screening of OSA-5, OSA-15, and of OSA-30, No-Apnea model showed the following parameters: sensitivity ranged from 83.1% to 91.5%, specificity ranged from 58.2% to 36.8%, whereas the accuracy ranged from 77.2% to 56.4%, respectively. All models tested (NoApnea, STOP-BANG, and NoSAS) were correlated with AHI (r s = 0.528, r s = 0.584, and r s = 0.534; respectively; all with P < .001). All AUCs obtained by the three models are shown in Figure 1 . No-Apnea scoring system is a 2-item model: neck circumference is scored as follows: 37.0-39.9 cm (1 point), 40.0-42.9 cm (3 points), and ≥ 43.0 cm (6 points), whereas age is scored as follows: 35-44 years (1 point), 45-54 years (2 points), ≥ 55 years (3 points); totaling a score of 0-9 points. Data are presented as estimates (95% confidence intervals) unless otherwise stated. AHI = apnea-hypopnea index, LR = likelihood ratio, NPV = negative predictive value, PPV = positive predictive value.
DISCUSSI ON
Our findings show that, in a sleep-laboratory setting containing a sample of subjects referred for evaluation of suspected OSA, an extremely simple tool, No-Apnea, designed with only two numeric and objectively acquired variables (NC and age) exhibits excellent and reproducible performance when screening for OSA at any level of severity. In both derivation and validation cohorts, the No-Apnea discrimination (a 2-item tool) did not significantly differ from that of STOP-BANG (an 8-item tool) and NoSAS (a 5-item tool). As expected, both cohorts presented a high prevalence of OSA, an anticipated finding Data are presented as estimates (95% confidence intervals) unless otherwise stated. No-Apnea scoring system is a 2-item model: NC is scored as follows: 37.0-39.9 cm (1 point), 40.0-42.9 cm (3 points), and ≥ 43.0 cm (6 points), whereas age is scored as follows: 35-44 years (1 point), 45-54 years (2 points), ≥ 55 years (3 points); totaling a score of 0-9 points (score ≥ 3 was considered as high-risk for presence of any OSA, moderate/severe OSA, and severe OSA). STOP-BANG questionnaire is an 8-item model (1 point for each positive answer): loud snoring, tiredness, observed apnea, hypertension, BMI > 35 kg/m 2 , age > 50 years, NC > 40 cm, and male sex; totaling a score of 0-8 points (score ≥ 3 was considered as high-risk for presence of any OSA, moderate/severe OSA, and severe OSA). NoSAS score is a 5-item model: NC > 40 cm (4 points), BMI 25.0-29.9 kg/m 2 (3 points), BMI ≥ 30.0 kg/m 2 (5 points), snoring (2 points), age > 55 years (4 points), male sex (2 points); totaling a score of 0-17 points (score ≥ 8 was considered as high risk for presence of any OSA, moderate/severe OSA, and severe OSA). AHI = apnea-hypopnea index, AUC = area under the curve, BMI = body mass index, LR = likelihood ratio, NC = neck circumference, NPV = negative predictive value, OSA = obstructive sleep apnea, PPV = positive predictive value. because these were clinically referred sleep-laboratory patients, a population known to have a high prevalence of OSA. According to previous studies, 8, 10, [23] [24] [25] our findings showed that males had higher NC than females, whereas females were older when compared with males. Similarly, we also observed that men had a higher rate of OSA compared to women. [3] [4] [5] 8, 10, [23] [24] [25] The cutoff used to classify patients with high pretest probability of OSA was 3 points for OSA-5, OSA-15, and OSA-30. The inclusion of this single cutoff was chosen to obtain a high sensitivity with consequent moderate specificity. Sensitivity and specificity of a screening model are usually inversely related, and the high sensitivity often comes at the expense of specificity. For a disease such as OSA, it is possibly more important that a screening test has a high sensitivity, and does not miss patients with OSA, rather than a high specificity, especially in a population with high pretest probability of disease. 10 However, this strategy may not be unanimous. A previous study 26 reports on the strategy of using different cutoffs to rulein or rule-out OSA. In a sleep-laboratory setting, where the main objective is to identify subjects with more severe forms of OSA and requiring treatment with continuous positive airway pressure (CPAP), a higher cutoff for a given model may be preferred, whereas in a primary care setting where the priority is not to miss any disease, a lower cutoff may be more appropriate. 26 Similar to prior studies on STOP-BANG, 27-29 as the No-Apnea score increased, the posttest probability of having OSA-5, OSA-15, and OSA-30 also increased.
OSA is a very prevalent and often underdiagnosed disease. 30, 31 In addition, symptoms suggestive of OSA, despite being common, are not consistently investigated during routine clinical visits. 32 Accordingly, screening tools can be used to identify patients at high risk for SDB, thus prioritizing the use of portable methods in areas with limited resources. However, the performance of an OSA questionnaire may have considerable variability according to the patient population and AHI thresholds employed. 10, 33 The Berlin questionnaire, for example, possibly has a better performance in primary care settings than sleep laboratory settings. 26, 34 In a sleep clinic population, the STOP-BANG showed sensitivity of 90%, 94%, and 96% to detect OSA-5, OSA-15, and OSA-30, respectively; however, specificity was relatively low (49%, 34%, and 25%; respectively). 35 Conversely, STOP-BANG alone was insufficient to confirm the occurrence of significant OSA in military veterans undergoing unattended sleep studies, mainly OSA-15, in whom a score of 3 showed a high sensitivity (99.1%), but also a very low specificity (4.9%).
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The STOP-BANG is an instrument with high sensitivity that increases in parallel with increasing AHI thresholds (from 5 to 30 events/h). 13 Conversely, it exhibits moderate to low specificity based on the AHI thresholds used herein, such that decreases in specificity result in a large number of false-positive results, thereby reducing accuracy, especially in the more severe forms of OSA. This issue is critical, particularly in sleep laboratories targeting the choice of portable diagnostic methods or when predicting which subjects will be requiring CPAP treatment.
The abilities of the 4-Variable screening tool, STOP, STOP-BANG, and ESS questionnaires in identifying subjects at risk for SDB were previously evaluated 37 : for predicting OSA-15, the STOP-BANG had the highest sensitivity (87.0%) with an AUC of 0.64, whereas the 4-Variable screening tool had the highest specificity (93.2%) and accuracy (79.4%). Moreover, predictive parameters for OSA-30 showed that the STOP-BANG had the highest sensitivity (70.4%), whereas the 4-Variable screening tool had the highest specificity (93.2%) and accuracy (86.7%) with an AUC of 0.67. Similar findings are shown in a study 38 comparing five different questionnaires (STOP, STOP-BANG, Berlin, ESS, and 4-Variable screening tool): the STOP-BANG had the highest sensitivity (97.6%) and the largest AUC (0.73), but the lowest specificity (12.7%) for OSA-15. Conversely, the 4-Variable screening tool had the highest specificity (74.4%) followed by ESS (67.0%).
According to NoSAS, although this instrument may possibly present good performances when other AHI thresholds are explored, it was implemented using an AHI cutoff of 20 events/h. 16 Conversely, our model was tested at three different AHI thresholds that are widely recognized and accepted when assessing the severity of OSA. The NoSAS score 16 has five variables (NC, BMI, age, sex, and snoring), whereas our tool requires only two objective parameters, a feature that we think can translate into greater practical applicability and ease of implementation. Moreover, NoSAS approach uses the presence of snoring as an integral parameter, thus requiring information based on a bed partner, thereby potentially resulting in information bias.
A recent study 39 was developed to validate the NoSAS score in a multiethnic Asian cohort and compare its performance with STOP-BANG and Berlin questionnaires: both questionnaires performed in a manner similar to that of the NoSAS score, with AUCs of all of them clustered around 0.682-0.748. Our study also did not verify performance differences between STOP-BANG and NoSAS, therefore different from the previous study of derivation and validation of NoSAS, in which it performed better than the STOP-BANG (P < .0001) and Berlin questionnaires (P < .0001) in both cohorts (HypnoLaus and EPISONO).
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Strengths and Limitations
Our study had some limitations: patient selection for generation of the tool was predicated on sleep laboratory subjects, and therefore the possibility of selection bias is plausible and its implication for the general population may be limited. In general, patients referred to a sleep laboratory are often suspected of having OSA and they reflect selected patients with a high pretest probability. Furthermore, possible specific differences in the tool properties among sexes may require future optimizing adjustments. A finding that deserves to be emphasized is that our 2-item model uses a parameter (NC) that can suffer from measurement error, which can cause information bias. In addition, it can be influenced by populations with their own anthropometric characteristics (Asian or African populations), thus requiring further validation in these settings. Similarly, measures of regional obesity were not included, and might provide important additional information to the referral decisionmaking algorithm.
Conversely, we should also point out several features of the current study that should strengthen the ability to implement the proposed instrument. First, the tool is a mnemonic and concise model with only two numerical and readily measured objective variables along with absence of any subjectively reported items, thereby allowing for easier acquisition and calculation while reducing potential biases. Second, it was developed and then validated in two large and independent cohorts, with all individuals enrolled undergoing full PSG and with the same diagnostic criteria, 19 aiming to explore the robustness of our model. Third, the developed scoring system presented adequate performance (overall performance, discrimination, and calibration) in the derivation cohort as well as in a validation cohort.
CONCLUSI ONS
In conclusion, our tool shows favorable promise for screening of OSA at any level of severity, based on commonly and widely used AHI thresholds. This tool should enable allocation of patients to different severity types and corresponding priorities, and thus enable improved patient prioritization and resource allocation. In addition, there was no superiority of one model over the other, which highlights a very great practical applicability of the No-Apnea because it contains only two objective variables easily obtained during the evaluation of a patient with suspected OSA. Therefore, it can also be used in individuals who sleep alone, in whom subjective information about sleep is not necessarily available. As with any population study, future prospective exploration for other world regions and different clinical settings will be critical for widespread implementation of such simple tool. 
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